Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Crinetics Pharmaceuticals, Inc. (CRNX)  
$47.23 0.10 (0.21%) as of 4:30 Wed 6/5


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 73,491,000
Market Cap: 3.47(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $15.97 - $51.91
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Paltusotine is an oral selective nonpeptide somatostatin receptor type 2 agonists designed for the treatment of acromegaly and neuroendocrine tumors. CRN04777 is Co.'s investigational, oral, nonpeptide somatostatin receptor type 5 agonist designed for the treatment of congenital hyperinsulinism. CRN04894 is Co.'s investigational, oral, nonpeptide product candidate designed to antagonize adrenocorticotrophic hormone, or ACTH, intended for the treatment of diseases caused by excess ACTH.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 5,000 5,000
Total Buy Value $0 $0 $110,300 $110,300
Total People Bought 0 0 1 1
Total Buy Transactions 0 0 1 1
Total Shares Sold 300,664 346,622 687,544 747,414
Total Sell Value $14,107,627 $15,727,746 $24,812,926 $25,945,942
Total People Sold 7 7 8 8
Total Sell Transactions 10 17 26 42
End Date 2024-03-07 2023-12-05 2023-06-06 2022-06-06

   
Records found: 186
  Page 4 of 8  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Betz Stephen F. Chief Scientific Officer   •       –      –    2023-03-01 4 A $0.00 $0 D/D 23,600 88,289     -
   Struthers Richard Scott President & CEO   •       •      –    2023-03-01 4 A $0.00 $0 D/D 61,650 130,150     -
   Hassard James Chief Commercial Officer   •       –      –    2023-03-01 4 A $0.00 $0 D/D 14,000 14,000     -
   Wilson Marc CFO   •       –      –    2023-03-01 4 A $0.00 $0 D/D 24,200 107,746     -
   Krasner Alan Seth Chief Medical Officer   •       –      –    2023-03-01 4 A $0.00 $0 D/D 19,500 43,988     -
   Betz Stephen F. Chief Scientific Officer   •       –      –    2023-02-01 4 AS $19.59 $61,238 D/D (3,126) 64,689 5%     
   Betz Stephen F. Chief Scientific Officer   •       –      –    2023-01-25 4 AS $21.07 $175,640 D/D (8,336) 67,815 3%     
   Betz Stephen F. Chief Scientific Officer   •       –      –    2023-01-17 4 AS $18.00 $56,268 D/D (3,126) 76,151 15%     
   Betz Stephen F. Chief Scientific Officer   •       –      –    2023-01-03 4 AS $18.35 $57,362 D/D (3,126) 79,277 23%     
   Betz Stephen F. Chief Scientific Officer   •       –      –    2022-12-15 4 AS $16.00 $50,016 D/D (3,126) 82,403 15%     
   Betz Stephen F. Chief Scientific Officer   •       –      –    2022-12-01 4 AS $17.84 $55,768 D/D (3,126) 84,968 -6%     
   Betz Stephen F. Chief Scientific Officer   •       –      –    2022-11-15 4 AS $18.72 $58,519 D/D (3,126) 88,094 -13%     
   Betz Stephen F. Chief Scientific Officer   •       –      –    2022-11-01 4 AS $18.52 $57,894 D/D (3,126) 91,220 -7%     
   Betz Stephen F. Chief Scientific Officer   •       –      –    2022-10-17 4 AS $17.73 $55,424 D/D (3,126) 94,346 8%     
   Struthers Richard Scott President & CEO   •       •      –    2022-10-12 4 OE $1.91 $21,201 D/D 11,100 68,500     -
   Pizzuti Dana Chief Development Officer   •       –      –    2022-10-10 4 A $0.00 $0 D/D 12,500 12,500     -
   Betz Stephen F. Chief Scientific Officer   •       –      –    2022-10-03 4 AS $19.64 $61,395 D/D (3,126) 97,472 6%     
   Betz Stephen F. Chief Scientific Officer   •       –      –    2022-09-15 4 AS $21.01 $87,570 D/D (4,168) 100,598 -5%     
   Betz Stephen F. Chief Scientific Officer   •       –      –    2022-09-07 4 AS $21.00 $21,884 D/D (1,042) 104,766 -12%     
   Betz Stephen F. Chief Scientific Officer   •       –      –    2022-09-01 4 AS $18.59 $58,112 D/D (3,126) 105,808 -8%     
   Knight Jeff E. Chief Operating Officer   •       –      –    2022-07-26 4 S $20.70 $23,847 D/D (1,152) 4,950 12%     
   Fust Matthew K Director   –       •      –    2022-07-13 4 AS $20.96 $119,455 D/D (5,700) 12,536 -19%     
   Fust Matthew K Director   –       •      –    2022-07-13 4 OE $1.45 $8,265 D/D 5,700 18,236     -
   Betz Stephen F. Chief Scientific Officer   •       –      –    2022-05-20 4 A $11.02 $14,723 D/D 1,336 108,934     -
   Knight Jeff E. Chief Operating Officer   •       –      –    2022-05-20 4 A $17.44 $20,091 D/D 1,152 6,102     -
  186 Records found
  1  2  3  4  5  6  7  8   
  Page 4 of 8
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us